Characterization of Coxsackievirus A6- and Enterovirus 71-Associated Hand Foot and Mouth Disease in Beijing, China, from 2013 to 2015 by Jie Li et al.
ORIGINAL RESEARCH
published: 30 March 2016
doi: 10.3389/fmicb.2016.00391
Frontiers in Microbiology | www.frontiersin.org 1 March 2016 | Volume 7 | Article 391
Edited by:
John W. A. Rossen,
University Medical Center Groningen,
Netherlands
Reviewed by:
Alina Deshpande,
Los Alamos National Laboratory, USA
Erguang Li,
Nanjing University, China
*Correspondence:
Yan He
heyanlb2014@163.com;
Quanyi Wang
bjcdcxm@126.com
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 09 December 2015
Accepted: 11 March 2016
Published: 30 March 2016
Citation:
Li J, Sun Y, Du Y, Yan Y, Huo D, Liu Y,
Peng X, Yang Y, Liu F, Lin C, Liang Z,
Jia L, Chen L, Wang Q and He Y
(2016) Characterization of
Coxsackievirus A6- and Enterovirus
71-Associated Hand Foot and Mouth
Disease in Beijing, China, from 2013
to 2015. Front. Microbiol. 7:391.
doi: 10.3389/fmicb.2016.00391
Characterization of Coxsackievirus
A6- and Enterovirus 71-Associated
Hand Foot and Mouth Disease in
Beijing, China, from 2013 to 2015
Jie Li 1, 2, Ying Sun 2, Yiwei Du 2, Yuxiang Yan 1, Da Huo 2, Yuan Liu 2, Xiaoxia Peng 1,
Yang Yang 2, Fen Liu 1, Changying Lin 2, Zhichao Liang 2, Lei Jia 2, Lijuan Chen 2,
Quanyi Wang 2* and Yan He 1*
1Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing, China, 2Beijing
Center for Disease Prevention and Control, Institute for Infectious Disease and Endemic Disease Control, Beijing, China
Background: Etiology surveillance of Hand Foot and Mouth disease (HFMD) in
Beijing showed that Coxsackievirus A6 (CVA6) became the major pathogen of HFMD
in 2013 and 2015. In order to understand the epidemiological characteristics and
clinical manifestations of CVA6-associated HFMD, a comparison study among CVA6-,
EV71- (Enterovirus 71), and CVA16- (Coxsackievirus A16) associated HFMD was
performed.
Methods: Epidemiological characteristics and clinical manifestations among CVA6-,
EV71- and CVA16-associated mild or severe cases were compared from 2013 to 2015.
VP1 gene of CVA6 and EV71 from mild cases, severe cases were sequenced, aligned,
and compared with strains from 2009 to 2015 in Beijing and strains available in GenBank.
Phylogenetic tree was constructed by neighbor-joining method.
Results: CVA6 became the predominant causative agent of HFMD and accounted for
35.4 and 36.9% of total positive cases in 2013 and 2015, respectively. From 2013
to 2015, a total of 305 severe cases and 7 fatal cases were reported. CVA6 and
EV71 were responsible for 57.5% of the severe cases. Five out six samples from
fatal cases were identified as EV71. High fever, onychomadesis, and decrustation
were the typical symptoms of CVA6-associated mild HFMD. CVA6-associated severe
cases were characterized by high fever with shorter duration and twitch compared with
EV71-associated severe cases which were characterized by poor mental condition,
abnormal pupil, and vomiting. Poor mental condition, lung wet rales, abnormal pupil,
and tachycardia were the most common clinical features of fatal cases. The percentage
of lymphocyte in CVA6-associated cases was significantly lower than that of EV71.
High percentage of lymphocyte and low percentage of neutrophils were the typical
characteristics of fatal cases. VP1 sequences between CVA6- or EV71-associated mild
and severe cases were highly homologous.
Conclusion: CVA6 became one of the major pathogens of HFMD in 2013 and 2015
in Beijing. Epidemiological characteristics, clinical manifestations of CVA6-, EV71- and
CVA16-associated cases in this study enriched the definition of HFMD caused by different
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pathogens and shed light to accurate diagnosis, appropriate treatment and effective
prevention of HFMD.
Keywords: hand foot and mouth disease, epidemic, Coxsackievirus A6, enterovirus 71, clinical features
INTRODUCTION
Hand Foot and Mouth disease (HFMD) is a very common
infectious disease usually associated with children younger than
5 years old. It is characterized by fever, sores or ulcers in the
mouth and a rash with blisters. Until now there’s still no effective
treatment against this disease. In the past few decades, this disease
has been reported all over the world, especially in the Asian-
Pacific region (Pallansch Ma, 2001; Zhang et al., 2009; Xing et al.,
2014).
Human enteroviruses (HEVs) belong to the genus
Enterovirus, family Picornaviridae, and are divided into
four species: HEV-A, HEV-B, HEV-C, and HEV-D on the basis
of the phylogenetic properties of the viruses (Pöyry et al., 1996;
Hyypiä et al., 1997). HFMD is most often caused by HEV-A
species which now includes 18 serotypes (CVA2–8, CVA10,
CVA12, CVA14, CVA16, EV71, EV76, EV 89–92, and EV114;
Zhang et al., 2011). HEV-A species with CVA16 and EV71 are the
two major serotypes agents of HFMD. CVA16 has contributed to
the serious outbreaks of HFMD in China since 2008 (Xing et al.,
2014) and has been endemic in Southeast Asia and the Pacific
region for decades (Tu et al., 2007; Iwai et al., 2009). Illness
caused by CVA16 infection is usually mild (Chang et al., 1999),
whereas EV71, a neurotropic virus, is responsible for severe
central nervous system complications (Chang et al., 1999). Large
outbreaks caused by EV71 with high mortality and morbidity
have been reported in Taiwan (Ho et al., 1999), Anhui (Zhang
et al., 2010), Shandong (Zhang et al., 2009) in China, and some
other countries as well (Gilbert et al., 1988; Cardosa et al., 1999;
Ho et al., 1999; Chan et al., 2003).
In recent years, CVA6 was frequently associated
with HFMD outbreaks in some countries such as Japan
(Fujimoto et al., 2012), Singapore (Wu et al., 2010), Thailand
(Puenpa et al., 2013), Finland (Osterback et al., 2010) and
Spain (Guimbao et al., 2010; Haneke, 2010). In 2013, the
etiology surveillance system in Beijing, as well as some other
provinces or cities in China including Guangdong (Zeng et al.,
2015), Tianjin (Tan et al., 2015), Nanjing (Hu et al., 2015), and
Shenzhen (Li et al., 2014) found that positive rate of CVA6
increased dramatically and became one of the major pathogens
of HFMD. Since then, CVA6 has spread in the mainland China
and attracted considerable attention. However, few studies
were performed to compare the epidemiology, clinical features
among the different pathogen-associated HFMD in China,
which were essential for deeply understanding the features of
HFMD, and also be helpful for the diagnosis and treatment of the
disease.
Abbreviations:HFMD, Hand Foot and Mouth disease; CVA6, Coxsackievirus A6;
CVA16, Coxsackievirus A16; EV71, Enterovirus 71; NNIDSS, National Notifiable
Infectious Disease Surveillance System; MEGA6.06, Molecular Evolutionary
Genetics Analysis Version 6.06.
VP1 is the major surface-accessible protein in the mature
enterovirus virion (Acharya et al., 1989) and contains a number
of important neutralization epitopes (Minor, 1990). It has been
proved to have an excellent genetic correlation with the EV
serotype (Oberste et al., 1999a) and has been widely used for virus
identification and evolutionary studies (Oberste et al., 1999b).
In this study, we performed genetic analyses on VP1 sequences
of CVA6 and EV71 from mild and severe cases to investigate
if there’s any linkage between the VP1 sequence and disease
severity.
MATERIALS AND METHODS
Case Definitions
A clinical case of HFMD was defined as oral ulcers,
maculopapular or vesicular rash on the hands, feet and
buttock, accompanied with or without fever. Patients were
classified as severe if they had any neurological complications
(aseptic meningitis, encephalitis, encephalomyelitis, acute flaccid
paralysis, or autonomic nervous system dysregulation), or
cardiopulmonary complications (pulmonary edema, pulmonary
hemorrhage, or cardiorespiratory failure), or both (Xing et al.,
2014).
HFMD Surveillance System in Beijing
In China, since 2008, clinicians and hospitals are required to
report clinical cases of HFMD to National Notifiable Infectious
Disease Surveillance System (NNIDSS) within 24 h of diagnosis
(Xing et al., 2014). More than 400 hospitals located in Beijing
were involved in the surveillance system. All the clinically
diagnosed severe cases were transferred to two designated
hospitals, Ditan Hospital and Youan Hospital to get treatment.
In order to get the information about the causative agents of
HFMD, year-round etiology surveillance programwas conducted
as well. This etiology surveillance program was performed in
18 sentinel hospitals from 18 districts of Beijing. First five
outpatients diagnosed as HFMD each month in 18 hospitals
were included in this program. At each clinic, trained technician
collected throat swab samples from these patients for serotyping
with prior informed consent. All the specimens were sent to
district CDCwhere EV, EV71, and CVA16were identified by real-
time-PCR. Specimens of non-EV71, non-CVA16 EV was sent to
Beijing CDC for detail EV serotyping, virus isolating and VP1
gene sequencing.
Participants, Sample and Data Collection
from Mild HFMD Cases
According to the geographical distribution of 18 districts in
Beijing, 6 districts of Changping, Daxing, Fangshan, Haidian,
Shunyi, and Tongzhou which are around the downtown of
Beijing, were selected to participate in this study during July to
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December of 2013. The first 15 patients clinically diagnosed with
HFMD infection each week were included in this study and were
followed up two times for 9 weeks. Questionnaires were designed
and certain personnel were trained to collect information of all
infected cases through telephone counseling at the end of the first
month and the last day of the ninth week.
Participants, Sample and Data Collection
from Severe and Fatal HFMD Cases
In order to get more information about the severe cases, we
have attempted to collect the detailed information and specimens
from all of the severe cases in Beijing from 2013 to 2015. With
prior written informed consent, trained personnel filled out the
questionnaires and collected specimens which would be sent to
district CDC for agent identification. A comparison study of
epidemiology and clinical manifestations between CVA6-, and
EV71- associated severe HFMD cases was performed from 2013
to 2015.
Samples Processing Mode, Nucleotide
Extraction and Virus Identification
The specimens stored in MEM were vibrated violently for
1 min and centrifuged at 4000 g for 20 min prior to
nucleotide extraction. Total nucleotide extraction was carried
out with a Roche MagNA Pure LC 2.0 nucleic extraction system
(ROCHE, Co, USA) using MagNA Pure LC Total Nucleic Acid
Isolation Kit–Large Volume (ROCHE, Co, USA), according to
the manufacturer’s instructions. EV, EV71, and CVA16 were
identified with real time RT-PCR Kit (DAAN Gene, Guangzhou,
China). Serotype of non-EV71 non-CVA16 EV was identified
by detecting the VP1 region of enterovirus positive samples
according to the previously described method (Nix et al., 2006).
Complete nucleotide sequences of VP1 genes were amplified
using specific primers as previously described (Perera et al., 2007;
Zhang et al., 2009; Sinclair et al., 2014). PCR products of complete
VP1 genes were purified and sequenced using ABI PRISM310
Genetic Analyzer, respectively.
Phylogenetic Analysis of CVA6 and EV71
Strains from Mild and Severe Cases
In order to further investigate the homology of mild and
severe strains isolated from EV71 or CVA6 infective patients,
sequence analysis of the complete gene of VP1 was performed
using the Molecular Evolutionary Genetics Analysis Version 6.0
(MEGA6). The phylogenetic tree was constructed by neighbor-
joining method with bootstrapping of 1000 replicates. A total of
25 CVA6 isolates (21 isolates from mild cases and 4 from severe
cases) and 27 EV71 isolates (19 isolates from mild cases, 7 from
severe cases, and 1 from fatal case) which were representative
in Beijing were aligned and compared with the corresponding
region of CVA6 and EV71 isolates from 2009 to 2012 in Beijing
and strains available at GenBank.
Statistical Analysis
In this study, we found that CVA6, CVA16, and EV71 were the
major causative agents of mild HFMD and CVA6 and EV71 were
responsible for major part of the severe cases in Beijing. In order
to find out the typical features of mild cases and severe cases due
to different pathogens, epidemiological information and clinical
manifestations were compared.
Statistical analysis was conducted by SPSS17 software
(IBM SPSS Inc., Chicago, IL, USA). Abnormal distribution
continuous variables were described using median with 25th
and 75th percentiles. Frequencies and proportions were used for
categorical variables.
Nonparametric test (Kruskal–Wallis test) was used to
compare the abnormal distribution continuous variables among
three groups of CVA6-, CVA16- and EV71-associated mild cases.
Pearson’s χ2 test or Fisher’s exact test was used to compare the
difference of categorical variables among three groups of CVA6-,
CVA16- and EV71-associated cases. If the comparison showed
significant difference among three groups, Mann–Whitney U-
test corrected by Bonferroni test will be performed.
Nonparametric test (Mann–Whitney U-test) was used to
compare the difference of abnormal distribution continuous
variables between two groups of CVA6- and EV71-associated
severe cases. Pearson’s χ2 test or Fisher’s exact test was used
to compare the difference of categorical variables between two
groups of CVA6- and EV71-associated severe cases. A p-value
of<0.05 (2-sided significance testing) was considered statistically
significant in above analyses.
Ethics Statement
This study was in compliance with the Helsinki Declaration
and was approved by the Human Research Ethics Committee of
Beijing CDC. Sample collection in this study was agreed by either
the patient or the patient’s guardian as appropriate with prior
informed consent.
RESULTS
CVA6 Emerged as the Major Pathogen of
HFMD in 2013 and 2015
The epidemiology and pathogen distribution of HFMD cases in
Beijing from 2009 to 2015 was shown in Table 1. The annual
number of reported HFMD cases ranged from 24,264 to 47,440,
with the corresponding annual incidence rates ranged from 143.1
to 258.6 cases/100,000 populations. Patients less than 5 years of
age accounted for more than 80% of all reported cases, the male
cases were about 1.5 times of the female cases. The proportion
of severe and fatal cases reached the peak of 1.3% and 0.4‰,
respectively in 2010 (Table 1).
In 2009, 2011, 2012, and 2014, CVA16 was identified as the
major pathogen of HFMD. In 2010, EV71 replaced CVA16 and
became the most common pathogen associated with HFMD.
While in 2013, CVA6 surpassed both CVA16 and EV71, became
the predominant agent of HFMD and accounted for 35.4% of
total positive cases. In 2014, CVA6-associated cases decreased
and accounted for 3.1% of the positive cases. From January to
September in 2015, CVA6 positive rate increased sharply again,
overtook both CVA16 and EV71 and became the predominant
causative agent of HFMD and accounted for 36.9% of positive
cases (Figure 1).
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TABLE 1 | The epidemiology and pathogen distribution of HFMD cases in Beijing, China, 2009–2015.
Year 2009 2010 2011 2012 2013 2014 2015(Jan–Sep) Pa
Case Number 24264 45385 30843 38528 33144 47440 25111 NA
Population 16949994 17550006 1961257 20186012 20692994 21148000 NA NA
Incidence rate (/105) 143.1 258.6 157.3 190.9 160.2 224.3 NA NA
Male (%) 14826 (61.1) 27372 (60.3) 18474 (59.9) 23079 (59.9) 20392 (61.5) 27992(59.0) 14951(59.5) 0.212
Agea 2.0 (1.0–3.0) 2.0 (1.0–4.0) 3.0 (1.0–4.0) 3.0 (1.0–4.0) 2.0 (1.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0) <0.001
Fatal cases (‰) 4 (0.2) 18 (0.4) 5 (0.2) 4 (0.1) 2 (0.1) 2 (0.0) 1 (0.0) 0.005
Severe cases (%) 104 (0.4) 610 (1.3) 278 (0.9) 356 (0.9) 152 (0.5) 111(0.2) 42 (0.2) <0.001
Etiology examination (n) 1769 4174 3179 4791 2943 2570 1150 NA
EV Positive sample (n) 1204 2285 1508 2194 1762 1636 851 <0.001
EV71 (%) 420 (34.9) 950 (41.6) 608 (40.3) 738 (33.6) 458 (26.0) 616 (37.7) 111 (13.0) <0.001
CVA16 (%) 634 (52.7) 716 (31.3) 666 (44.2) 1191 (54.3) 519 (29.5) 729 (44.6) 246 (28.9) <0.001
Other EV (%) 150 (12.5) 602 (26.3) 223 (14.8) 233 (10.6) 870 290 494 <0.001
CVA6 (%) NA NA NA NA 623 (35.4) 50 (3.1) 314 (36.9) NA
CVA10 (%) NA NA NA NA 5 (0.3) 22 (1.3) 3 (0.4) NA
Agea, presented as median (p25, p75).
FIGURE 1 | Monthly distribution of enterovirus serotypes in
laboratory-confirmed HFMD cases in Beijing, during 2013 and 2015.
Epidemiology and Clinical Manifestations
of CVA6-, EV71,- and CVA16-Associated
Mild HFMD
From July through December of 2013, a total of 567 clinically
diagnosed HFMD patients from six districts of Beijing were
recruited and followed up 2 times for 9 weeks. All the patients
participated in this study were diagnosed as mild cases and were
successfully followed up. Among the patients, 62.4% (354/567)
were male and the median age was 37 months. About 60.0%
(340/567) cases were enterovirus positive and the proportion
of CVA6, EV71, CVA16, and other serotype EV was 21.2 %
(72/340), 21.2% (72/340), 42.9% (146/340), and 14.7% (50/340),
respectively (Table 2).
In order to get more detail information about the difference
among CVA6-, CVA16,- and EV71-associated mild cases,
epidemiological data and clinical features were compared and the
results were shown in Table 3. Both the proportion of cases with
symptom of fever and the proportion of cases with symptom of
fever over 39◦C among CVA6-associated cases were significantly
TABLE 2 | The total number of samples from mild cases, severe cases,
and fatal cases tested in this study.
Mild cases Severe cases Fatal cases
(n = 567) (n = 270) (n = 6)
Negative case (%) 227 (40.0) 110 (40.7) 1 (16.7)
Positive case (%) 340 (60.0) 160 (59.3) 5 (83.3)
CVA6 (%) 72 (21.2) 41 (25.6) 0 (0.0)
EV71 (%) 72 (21.2) 51 (31.9) 5 (100.0)
CVA16 (%) 146 (42.9) 18 (11.3) 0 (0.0)
Other EV (%) 50 (14.7) 50 (31.3) 0 (0.0)
higher than CVA16-(P< 0.001) and EV71-(P< 0.001) associated
cases. Desquamation on the palms and soles after infection
episode in CVA6-associated cases was significant higher than that
in the CVA16- associated cases (P = 0.016). Proportion of cases
with onychomadesis in CVA6-associated cases was significantly
higher than CVA16-(P < 0.001) and EV71- (P < 0.001). All
the patients with onychomadesis denied a past history of major
systemic disease or nail trauma in the 8 weeks prior to the onset
of the nail abnormalities.
Epidemiology and Clinical Manifestations
of CVA6- and EV71-Associated Severe
HFMD
A total of 305 clinically diagnosed severe HFMD cases were
reported from 2013 to the October in 2015. Information of
281 severe cases, which included 197 male and 84 female were
collected with the median age of 23 months. About 63.7%
(179/281) cases were initially diagnosed as HFMD. The most
common clinical manifestations of severe cases were fever (100%)
and rash (100%), followed by poor mental condition (50.9%),
hyperarousal (39.5%), tremble of hand and foot (36.3%), twitch
(31.3%), and vomiting (31.0%).
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TABLE 3 | Epidemiology and clinical features of CVA6-, EV71,- and CVA16-associated mild cases in Beijing, 2013.
Characteristics CVA6 (n = 72) CVA16 (n = 146) EV71 (n = 72) P Pa
CVA6 vs. CVA16 CVA6 vs. EV71 CVA16 vs. EV71
Age (month)b 35.5(18.5–53.5) 40.0(27.75–53.25) 34.0(17.0–51.5) 0.113 NA NA NA
SEX
Male (%) 41(56.9) 96(65.8) 51(70.8) 0.206 NA NA NA
OCCUPATION
Scattered children (%) 35(49.3) 54(37.0) 41(56.9) 0.053 NA NA NA
Children in Kindgarden (%) 29(40.8) 80(54.8) 26(36.1)
Primary school (%) 7(9.9) 12(8.2) 5(6.9)
bMedian duration from onset to
initial diagnosis
1(1.0–2.0) 1(0.0–1.0) 1(0.0–1.0) 0.010 0.011 0.006 0.475
bRash duration 2(1.0–3.0) 2(1.0–2.0) 1(1.0–2.0) 0.002 0.030 <0.001 0.064
RASH %
Hand 69(95.8) 141(96.6) 71(98.6) 0.621 NA NA NA
Foot 62(86.1) 112(76.7) 59(81.9) 0.240 NA NA NA
Mouth 58(80.6) 107(73.8) 50(69.4) 0.309 NA NA NA
Buttock 26(36.1) 37(25.5) 23(31.9) 0.241 NA NA NA
Vesicle 6(8.3) 12(8.2) 3(4.2) 0.509 NA NA NA
Pigmentation 9(12.5) 7(4.8) 3(4.2) 0.062 NA NA NA
Fever 53(73.6) 41(28.1) 26(36.1) <0.001 <0.001 <0.001 0.227
Fever (≥39◦C) 23(31.9) 11(7.5) 5(6.9) <0.001 <0.001 <0.001 0.875
Desquamation 28(38.9) 34(23.3) 16(22.2) 0.030 0.016 0.030 0.860
Onychomadesis 13(18.1) 0(0.00) 1(1.4) <0.001 <0.001 0.001 0.153
Pa <0.05/3 was considered to be significant.
bpresented as median (p25, p75).
P, from Pearson’s χ2, Fisher’s exact test or Rank test.
NA, data not available.
The bold values means significant difference was obtained between or among compared groups.
From 2013 to 2015, the throat swab samples from the 270
severe cases were collected and analyzed by real-time-PCR and
59.3% (160/270) cases were positive for enterovirus. The positive
proportion of CVA6, EV71, CVA16, and other serotype EV
were 25.6% (41/160), 31.9% (51/160), 11.3% (18/160), and 31.3%
(50/160), respectively (Table 2).
Characteristics of 33 CVA6- and 46 EV71-associated severe
cases with complete information were compared and the result
was showed in Table 4. Twenty-two (66.7%) of CVA6-associated
severe cases and thirty-two (69.6%) of EV71-associated cases
were male (P= 0.785) with the median ages of 22 and 23 months
(P = 0.505), respectively. The median duration from disease
onset to diagnosis as severe case among CVA6–associated severe
cases were significantly shorter than that of EV71-associated
severe cases (P = 0.002).
The fever peak of the whole disease course of CVA6-associated
severe case was significantly higher than that of EV71-associated
cases (P = 0.007) and the median duration of fever among
CVA6-associated cases was significantly shorter than that of
EV71-associated cases (P = 0.007). Furthermore, the incidence
of symptoms of poor mental condition, abnormal pupil and
vomiting among CVA6-associated cases was significantly lower
than that of EV71-associated cases (P = 0.038, P = 0.038,
P = 0.009), respectively. While the incidence of twitch among
CVA6-associated cases was significantly higher than that of
EV71-associated cases (P = 0.036). Additionally, Lymphocyte
percentage of CVA6 infected severe cases was significantly lower
than that of EV71 infected severe cases (P = 0.004).
Epidemiology and Clinical Manifestations
of Fatal HFMD Cases
From 2013 to 2015, a total of 7 fatal cases which included 5
permanent residents and 2 migrants were reported (Table 3).
Among the 7 fatal cases, 5 were male and the median age was 17.5
months. Five out of seven cases died in 3 days after HFMD onset.
A total of 6 samples were collected from fatal cases and 5 samples
were identified as EV71 positive. The most common clinical
manifestations of fatal cases were fever (100%) and rash (100%),
followed by poor mental condition (85.7%), lung wet rales
(71.4%), abnormal pupil (57.1%), tachycardia (57.1%), dysphoria
(42.9%), vomiting (42.9%), ecphysesis (42.9%), and pale face
and extremities (42.9%). The median WBC counts, median
lymphocyte percentage and median neutrophil percentage of
fatal cases were 20.2∗109/L, 72.6 and 22.4%, respectively. WBC
counts and lymphocyte percentage of all fatal cases were above
the upper limit of the normal range, while neutrophil percentage
of all fatal cases were lower than lower limit of the normal range.
Phylogenetic Analysis
All the CVA6 strains were classified into seven major clades (A–
G) (Figure 2). CVA6 isolates in this study from 2013 to 2015 (20
strains from mild cases and 4 strains from severe cases) were all
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TABLE 4 | Epidemiology and clinical features of CVA6- and EV71- associated severe HFMD cases.
Characteristics Severe cases (n = 281) Fatal cases (n = 7) Severe cases due to CVA6 or EV71
CVA6(n = 33) EV71(n = 46) Pa
bAge (month) 23(17.0–41.0) 17.0(12.0–25.0) 22(17.5–37.5) 23(15.8–44.3) 0.505
SEX (%)
Male 197(70.1) 5(71.4) 22(66.7) 32(69.6) 0.785
OCCUPATION (%)
Scattered children 194(69.0) 6(85.7) 26(78.8) 29(63.0) 0.133
Children in Kindgarden 86(30.6) 1(14.3) 7(21.2) 17(37.0)
Primary school 1(0.4) 0(0.0) 0(0.0) 0(0.0)
bMedian duration from onset to
diagnosis
0(0.0–1.0) 1.0(0.0–2.0) 0(0.0–1.0) 1(0.0–2.0) 0.031
Diagnosed as HFMD at the initial
visit (%)
179(63.7) 4(57.1) 20(60.6) 30(65.2) 0.675
bMedian duration from onset to
diagnosis of severe or death
case
2(1.0–3.0) 2(2.0–3.0) 1(1.0–2.0) 3(2.0–3.0) 0.002
bFever peak before visiting
hospital (◦C)
39(38.7–39.6) 38.9(38.5–39.3) 39.6(39–40) 39.0(38.6–39.3) 0.001
bFever peak of the whole
course (◦C)
39.2(38.9–39.7) 39.0(38.7–39.3) 39.8(39.2–40.0) 39.1(39.0–39.6) 0.007
bFever duration (day) 2(2.0–3.0) 3(3.0–4.0) 2(2.0–3.0) 3(2.0–4.0) 0.009
bRash duration (day) 3(2.0–4.0) 3(2.5–4.5) 3(2.0–4.0) 3(2.3–4.0) 0.252
RASH (%)
Hand 223(79.4) 5(71.4) 24(72.7) 42(91.3) 0.028
Foot 205(73.0) 5(71.4) 21(63.6) 41(89.1) 0.007
Mouth 218(77.6) 3(42.9) 30(90.9) 36(78.3) 0.135
Buttock 136(48.4) 2(28.6) 15(45.5) 25(54.3) 0.436
SYMPTOM OF NERVOUS SYSTEM (%)
Headache 41(14.6) 0(0.0) 5(15.2) 8(17.4) 0.791
Poor Mental condition 143 (50.9) 6(85.7) 13(39.4) 29(63.0) 0.038
Hyperarousal 111 (39.5) 2(28.6) 17(51.5) 26(56.5) 0.659
Dysphoria 26 (9.3) 3(42.9) 4(12.1) 7(15.2) 0.754
Twitch 88 (31.3) 2(28.6) 17(51.5) 13(28.3) 0.036
Seizures 26 (9.3) 2(28.6) 3(9.1) 3(6.5) 0.671
Tremble of hand and foot 102 (36.3) 2(28.6) 16(48.5) 27(58.7) 0.369
Limb weakness 14 (5.0) 2(28.6) 3(9.1) 2(4.3) 0.644
Neck resistance 4(1.4) 0(0.0) 0(0.0) 1(2.2) 1.000
Abnormal tendon reflexes 6(2.1) 2(28.6) 0(0.0) 4(8.7) 0.136
Drowsiness 29 (10.3) 1(14.3) 2(6.1) 7(15.2) 0.291
Lethargy 7(2.5) 0(0.0) 0(0.0) 3(6.5) 0.261
Coma 5(1.8) 2(28.6) 0(0.0) 2(4.3) 0.507
Abnormal pupil 13(4.6) 4(57.1) 0(0.0) 7(15.2) 0.038
Vomiting 87 (31.0) 3(42.9) 7(21.2) 23(50) 0.009
SYMPTOM OF RESPIRATORY SYSTEM (%)
Cough 44 (15.7) 2(28.6) 4(12.1) 8(23.9) 0.520
Ecphysesis 13 (4.6) 3(42.9) 1(3.0) 6(13.0) 0.229
Dyspnea 7(2.5) 2(28.6) 0(0.0) 4(8.7) 0.136
Lung wet rales 9(3.2) 5(71.4) 0(0.0) 4(8.7) 0.136
SYMPTOM OF CIRCULATORY SYSTEM (%)
Cyanose of fingers, toes or lips 15 (5.3) 1(14.3) 2(6.1) 2(4.3) 1.000
Pale face and extremities 7(2.5) 3(42.9) 1(3.0) 3(6.5) 0.636
Pale body 3(1.1) 1(14.3) 0(0.0) 3(6.5) 0.261
Tachycardia 59 (21.0) 4(57.1) 7(21.2) 13(28.3) 0.477
Coolness of extremities 15(5.3) 2(28.6) 2(6.1) 4(8.7) 1.000
(Continued)
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TABLE 4 | Continued
Characteristics Severe cases (n = 281) Fatal cases (n = 7) Severe cases due to CVA6 or EV71
CVA6(n = 33) EV71(n = 46) Pa
LABORATORY TEST
WBC(109/L) 11.9(9.5–15.1) 20.2(11.7–31.0) 12.8(11.1–16.4) 11.8(9.1–14.7) 0.132
Lymphocyte (%) 25.1(17.2–35.8) 72.6(61.4–77.4) 20.1(13.9–30.7) 28.5(22.0–37.9) 0.004
Neutrophil (%) 64.8(51.8–74.4) 22.4(15.4–31.1) 66.8(52.3–76.1) 64.9(51.9–72.2) 0.490
Pa, from Chi-square test, Fisher’s exact test or Mann–Whitney U-test corrected by Bonferroni test.
bpresented as median (p25, p75).
The bold values means significant difference was obtained between or among compared groups.
located in cluster G. The nucleotide and amino acid identities
of the VP1 gene among mild CVA6 strains were 94.1–98.3%
and 96.8–100.0%. The nucleotide and amino acid identities of
the VP1 gene among severe CVA6 strains were 95.7–99.4% and
98.9–100.0%. CVA6 strains from mild cases shared nucleotide
identity of 94.5–99.4% and amino acid identities of 97.8–99.5%
with the strains from severe cases. Compared with CVA6 strains
from severe cases in Shenzhen from 2009 to 2012, CVA6 isolates
from severe cases in Beijing shared a nucleotide and amino acid
identity of 94.5–98.5 and 97.8–99.6%.
EV71 isolates in this study from 2007 to 2015 (19 strains from
mild cases, 7 strains from severe cases, and 1 strain from fatal
case) were all located in the cluster of C4a genotype (Figure 3).
The nucleotide and amino acid identities of the VP1 gene
among mild EV71 strains were 93.3–99.9 and 97.5–100.0%. The
nucleotide and amino acid identities of the VP1 gene among
severe and fatal EV71 strains were 94.7–99.5 and 98.6–100.0%.
EV71 strains from mild cases shared nucleotide identity of 93.3–
98.9% and amino acid identities of 97.9–100.0% with the strains
from severe and fatal cases. Compared with EV71 strains from
severe cases or fatal cases in Anhui and Shandong, EV71 isolates
from severe and fatal cases in Beijing shared a nucleotide identity
of 92.4–98.7%, with the corresponding amino acid identity of
about 98.6–100.0%.
DISCUSSION
In the past decade, numerous epidemics of HFMD have occurred
in the Asia-Pacific region, which were mainly caused by EV71
and CVA16. Since 2013, the positive proportion of CVA6 has
increased greatly and became the predominant pathogen of
HFMD in several provinces of China (Hongyan et al., 2014; Lu
et al., 2014; Tan et al., 2015; Zeng et al., 2015). The etiology
surveillance on thousands of HFMD cases each year from 2009
to 2012 in Beijing showed that the positive rates of non-CVA16
and non-EV71 EV-associated cases ranged from 10.6 to 26.3%.
The present study showed that CVA6 alone accounted for 35.4%
(2013) and 36.9% (2015) of the total positive cases and surpassed
CVA16 and EV71 became the predominant strain in Beijing.
This observation suggested that non-CVA16, non-EV71 EV-
associated HFMD should be monitored closely in order to give
early warning when new serotypes emerge so as to downsize the
prevalence and reduce the infected cases.
It has been reported that high fever (Lo et al., 2011),
onychomadesis (Osterback et al., 2010; Wei et al., 2011; Fujimoto
et al., 2012), pigmentation (Wei et al., 2011; Huang et al.,
2013), vesicular rash (Ben-Chetrit et al., 2014; Feder et al., 2014;
Hu et al., 2015), and desquamation (Feder et al., 2014) are
associated with the CVA6 infected patients. In this study, results
indicated that high fever, desquamation and onychomadesis
were characterized manifestations of CVA6-associated cases.
Pediatricians should be alert for the above characterized clinical
presentations so that appropriate treatment measures could
be provided. On the other hand, the above typical features
of CVA6-associated mild cases might enrich the definition of
HFMD which is very important for the disease prevention and
control and provide useful information for the further study in
the burden of disease.
In our study, we found that the total number of severe cases
of HFMD in Beijing had an obviously drop from 2010 to 2015
which was in agreement with result of previous study (Huang
et al., 2015). EV71 was still the leading serotype responsible for
severe HFMD cases, especially fatal HFMD cases. While with
the CVA6 becoming the major pathogen of HFMD, it accounted
for an increase of severe cases in 2013 and 2015. Similar to
the mild cases, the fever peak of CVA6-associated severe cases
was significantly higher than that of EV71 infected cases which
was accordant with previously reported studies (Hongyan et al.,
2014; Yang et al., 2014). Based on the result we suspected
that hyperpyrexia which was the typical clinical manifestation
of CVA6 might have driven the parents or guardians to take
their children to the hospital. As a result, patient’s visiting to
hospital and diagnosis of severe cases among CVA6 patients were
significantly earlier than EV71 which might be a protective factor
of a better prognosis. It has been widely known that EV71 is in
its neurotropism to cause neurological complications (Wang and
Liu, 2014). In this study we found that poor mental condition,
abnormal pupil, and vomiting were the typical symptoms of
EV71-associated severe cases compared with CVA6-associated
severe cases. Besides fever and rash, poor mental condition,
lung wet rales, abnormal pupil, and tachycardia were the most
common clinical features of fatal cases. In this study, we observed
about 36.3% severe cases and 42.9% fatal cases weremisdiagnosed
as the other disease at the initial visit to the hospital. According
to a previous study (Pan et al., 2012), unable to be diagnosed as
HFMD in the first visit to the hospital was an important risk
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FIGURE 2 | Phylogenetic dendrogram based on the alignment of the complete VP1 gene sequence of CVA6 (915bp). CVA6 strains isolated from mild cases,
severe cases in Beijing were indicated by a red triangle, a red dot, respectively. CVA6 strains isolated from severe cases in other cities were indicated by a blue dot.
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FIGURE 3 | Phylogenetic dendrogram based on the alignment of the complete VP1 gene sequence of EV71 (891bp). EV71 strains isolated from mild cases,
severe cases and fatal cases in Beijing were indicated by a red triangle, a red dot and a red square, respectively. EV71 strains isolated from severe cases and fatal
cases in other cities were indicated by a blue dot and a blue square, respectively.
factor of severe HFMD. Based on the above results we believed
that a clear understanding of the disease might improve the
diagnostic accuracy and therefore, appropriate treatment can be
performed. On the other hand, the disease course of severe or
fatal case was a continuous and dynamic procedure. It may be a
reversible disease if the clinical symptoms were recognized in the
early stage. Considering the rapid progression of this disease in
which 5 out of 7 severe cases died in the first 3 days, we proposed
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that typical features were valuable for the clinician making a
diagnosis as well as evaluating the stage of disease progression
and thereby preventive measures could be instituted and effective
treatment could be performed.
The response of the immune system of enterovirus infected
cases was also evaluated. Our study showed that lymphocyte
percentage of some CVA6- or EV71-associated severe cases were
below the lower limit of normal range. This phenomenon was
accordant with the result of Wang’s study (Wang et al., 2003)
in which the absolute lymphocyte count decreased dramatically
at first and returned in several days. However, the lymphocyte
percentage of all the fatal cases was much higher than the upper
limit of normal range and the neutrophil percentage of all the
fatal cases was lower than the lower limit of normal range.
Based on this result, we suggested that dramatically increased
lymphocyte percentage and decreased neutrophil percentage
might be a sign of worsen condition. This could be used as a
functional marker for EV71-related cases and potential treatment
options.
Furthermore, in our study, EV71 was responsible for 5 out of 6
fatal cases. This result suggested that although the proportion of
EV71 declined in recent years, considering that EV71 was prone
to cause severe cases, even death, strategy of how to prevent the
spreading of EV71 should still be paid attention to. Nowadays,
many studies on EV71 vaccine are ongoing and three vaccines
had completed their clinical trial (Zhu et al., 2013, 2014; Li et al.,
2015). Previous clinical trials studies showed that EV71 vaccines
were efficacy and safety, but did not protect the population
from other serotypes infection (Chou et al., 2012; Chong et al.,
2015). Considering the great change in the HFMD epidemic
pattern, we suggested that the trend of HFMD epidemic should
be monitored closely and the vaccine strategies against HFMD
should be formulated based on the epidemic situation of HFMD.
In this study, both strains from mild and severe cases
of CVA6 or EV71 were all located on the same cluster of
the phylogenetic tree, indicating that they shared the single
ancestor and were undistinguishable only depending on the
VP1 sequence. According to a previous study, VP1-145E
variants were mainly responsible for the development of viremia
and neuropathogenesis and involving in the vivo fitness, and
pathogenesis in EV71-infected individuals (Chang et al., 2012).
In our study, we didn’t find a link between the 145th amino acid
of VP1 and disease severity, since 145E was a predominant form
in both mild and severe cases. We suggested that severe cases
couldn’t be distinguished from mild cases only depending on the
amino acid on this site. From our point, the immune response
status of the host might play essential role in the whole course
as well. Till now, there is no confirmative evidence about what
kind of strains are prone to cause severe even fatal cases and what
kind of person are easy to develop to severe case. Hence, more
information, such as the genome of pathogen and the dynamic
immunity status of host are needed to carry out further study.
In conclusion, CVA6 became the predominant causative
agent of HFMD in Beijing, China, in 2013 and 2015. CVA6
and EV71 accounted for the majority of severe HFMD. Non-
CVA16, non-EV71 EV-associated HFMD should be monitored
closely in order to give early warning when new serotypes
emerge so as to downsize the prevalence and reduce the infected
cases. Typical clinical features enriched the definition about
CVA6- and EV71-associated HFMD and were helpful for the
diagnosis and treatment of the disease. EV71 was responsible
for most of the fatal cases. Vaccine strategy against EV71
should be formulated base on the current epidemic situation
of HFMD.
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